Financial Performance - The company achieved operating revenue of ¥272,363,007.16, representing a year-on-year increase of 5.79%[21]. - Net profit attributable to shareholders reached ¥90,000,334.06, a significant increase of 42.90% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥85,511,621.61, up 38.03% year-on-year[21]. - Basic and diluted earnings per share were both ¥1.1221, reflecting a growth of 22.49%[21]. - Total assets at the end of the reporting period were ¥1,986,419,318.93, an increase of 104.72% compared to the end of the previous year[21]. - The company's net assets attributable to shareholders rose to ¥1,799,306,725.74, marking a 142.22% increase year-on-year[21]. - The main business segments generated operating revenue of ¥27,236.30 million, with a 5.79% year-on-year growth[32]. - The sales revenue from the lipoic acid series was ¥21,558.81 million, up 9.29% year-on-year[32]. - The company's revenue for the reporting period reached ¥272,363,007.16, representing a year-on-year increase of 5.79%, primarily driven by the growth in sales of lipoic acid series products[45]. Cash Flow and Financing - The company reported a net cash flow from operating activities of ¥54,220,954.79, a decrease of 52.01% from the previous year[21]. - The company reported a significant increase in cash flow from financing activities, amounting to ¥943,262,554.75, a 5,000.92% increase due to funds raised from the initial public offering[45]. - The cash and cash equivalents decreased by 77.73% to ¥46,628,682.02, primarily due to increased inventory and procurement payments[45]. - The company raised ¥1,024,008,300.00 through financing activities in the first half of 2022, compared to ¥18,562,621.00 in the same period of 2021[154]. - The net cash flow from financing activities was ¥943,262,554.75, an increase from ¥18,492,018.60 in the first half of 2021[156]. Research and Development - R&D expenses for the first half of 2022 amounted to 20.37 million yuan, a year-on-year increase of 41.97%, representing 7.48% of total revenue, the highest in the company's history[37]. - Research and development investment increased by 41.97% to ¥20,371,664.17, reflecting the company's commitment to enhancing its R&D capabilities[45]. - The company is focusing on expanding its CMO/CDMO business and accelerating the development of specialty raw material drug pipelines[32]. - The company has submitted registration materials for the commercialized project of Apatinib raw materials to the National Medical Products Administration, with expected supply to a partner by the end of 2023[36]. Environmental Management - The company has implemented a comprehensive environmental management system and has passed the ISO 14001:2015 certification, reflecting its commitment to environmental protection[74]. - The company has established a comprehensive environmental protection system combining clean production and end-of-pipe treatment to ensure compliance with emission standards[86]. - The company has maintained compliance with environmental regulations, with all wastewater, waste gas, and noise treatment results meeting standards during the reporting period[90]. - The company has implemented measures to control emissions of volatile organic compounds, including toluene and xylene, with emissions recorded at 0.067 mg/L and 0.0023 mg/L respectively, both within limits[85]. Risk Management - The company faced various operational risks, which are detailed in the section discussing risks and countermeasures[4]. - The company has established a risk control system for derivative trading to mitigate market and liquidity risks, ensuring no speculative trading activities are conducted[67]. - The company has established a risk management mechanism to monitor and respond to fluctuations in foreign exchange rates, utilizing derivatives to minimize risks[76]. Corporate Governance - The financial report was confirmed to be true, accurate, and complete by the company's management, including the legal representative and accounting heads[4]. - The company has maintained a stable management team with no changes in directors or senior management during the reporting period[80]. - The company has not reported any overdue or unrecovered amounts from entrusted financial management[66]. - The company has not engaged in any major asset or equity sales during the reporting period, indicating stability in its asset management[71][72]. Shareholder Information - The company completed its initial public offering (IPO) of 22.92 million shares, increasing total share capital to 91.67 million shares[120]. - The proportion of restricted shares decreased from 100% to 76.29% after the IPO, with 69.93 million shares now unrestricted[119]. - The total number of shareholders at the end of the reporting period was 20,413, with the largest shareholder holding 60.22% of the shares, equivalent to 55,200,000 shares[126]. Social Responsibility - The company donated a total of 200,000 RMB to local charities and engaged in various social responsibility initiatives, including employment for disabled individuals[92]. - The company has established a comprehensive employee social insurance management system, ensuring labor rights and promoting harmonious labor relations[91].

苏州富士莱医药股份有限公司 投资者关系活动记录表 证券代码：301258 证券简称：富士莱 编号：20220506 | --- | --- | --- | --- | |-------------------------|-------------------------------------------------|------------------------------------------------|----------------------------------------------------------------| | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | √业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | □其他 | | | 参与单位名称及 人员姓名 | 参加公司 2021 | 年度网上业绩说明会的投资者 | | | | | | | | 时间 | 2022 年 05 月 06 | 日（周五） 15:00-17:00 | | | 地点 | 公司通过全景网 " | 投资者关系互动平台 " ...

Financial Performance - The company's revenue for Q1 2022 was ¥141,779,121.55, representing a 23.23% increase compared to ¥115,048,307.15 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was ¥39,919,425.66, a 48.50% increase from ¥26,881,293.96 in Q1 2021[3] - Total operating revenue for Q1 2022 was CNY 141,779,121.55, an increase of 23.2% compared to CNY 115,048,307.15 in the same period last year[19] - Net profit for Q1 2022 reached CNY 39,919,425.66, representing a 48.5% increase from CNY 26,881,293.96 in Q1 2021[21] - Basic earnings per share for Q1 2022 were ¥0.58, up 48.72% from ¥0.39 in the same period last year[3] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.58, compared to CNY 0.39 in the previous year[22] - The company reported a gross profit margin of approximately 28.0% for Q1 2022, compared to 26.0% in Q1 2021[19] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 65.74%, amounting to ¥22,441,786.64 compared to ¥65,504,996.03 in the previous year[7] - Cash inflow from operating activities totaled CNY 131,694,495.16, slightly down from CNY 141,081,132.64 in Q1 2021[24] - The net cash flow from operating activities was CNY 22,441,786.64, a decrease of 65.7% compared to CNY 65,504,996.03 in the previous year[25] - The total cash inflow from investment activities was CNY 31,345,383.92, down from CNY 81,319,856.74, resulting in a net cash flow from investment activities of -CNY 3,171,032.05[25] - The cash inflow from financing activities amounted to CNY 1,024,008,300.00, with a net cash flow of CNY 999,147,447.26 after outflows[25] - The net increase in cash and cash equivalents for the quarter was CNY 1,017,179,734.08, compared to CNY 110,438,709.94 in the same period last year[26] - The ending balance of cash and cash equivalents was CNY 1,329,798,336.02, significantly higher than CNY 179,730,004.14 at the end of the previous year[26] - The company reported a total cash outflow from operating activities of CNY 109,252,708.52, compared to CNY 75,576,136.61 in the previous year[25] Assets and Liabilities - Total assets at the end of Q1 2022 reached ¥1,995,766,346.91, a 105.68% increase from ¥970,306,076.54 at the end of the previous year[3] - Total liabilities as of Q1 2022 were CNY 209,872,529.57, down from CNY 227,466,681.73 in the previous year[19] - The company’s non-current assets totaled RMB 444,226,849.03, down from RMB 453,707,308.62, indicating a decrease of about 2.6%[17] Shareholder Information - Shareholders' equity attributable to the company's shareholders increased by 140.41% to ¥1,785,893,817.34 from ¥742,839,394.81[3] - The number of ordinary shareholders at the end of the reporting period was 29,050[9] - The total cash dividend distributed to shareholders is RMB 36,668,000, amounting to RMB 4.00 per 10 shares based on a total share capital of 91,670,000 shares[14] - The company has a total of 69,934,117 restricted shares at the end of the reporting period, with 1,184,117 shares newly added during the period[12] - The company has committed to a lock-up period for various shareholders, with the longest being 36 months for certain shares[12] Expenses and Investments - Total operating costs for Q1 2022 were CNY 102,613,441.78, up 21.7% from CNY 84,280,159.80 in Q1 2021[19] - Research and development expenses for Q1 2022 amounted to CNY 8,771,509.27, an increase from CNY 7,647,211.67 in the same period last year[19] - The cash paid to employees increased to CNY 22,497,138.22 from CNY 19,456,055.40 year-over-year[25] - The cash paid for taxes was CNY 5,952,602.80, up from CNY 1,934,239.13 in the previous year[25] - The cash received from investment income was CNY 149,589.03, a decrease from CNY 1,046,782.10 in the previous year[25] Other Information - The company received government subsidies amounting to ¥6,095,236.87 during the reporting period[5] - The company did not conduct an audit for the first quarter report[27] - The company reported a total of RMB 22,517,775.52 in intangible assets, slightly increasing from RMB 22,074,780.72[17] - Deferred income tax liabilities were CNY 17,403,017.28, slightly down from CNY 17,880,478.20 in the previous year[19]

Financial Performance - The company's operating revenue for 2021 was ¥521,695,665.95, representing a 9.40% increase compared to ¥476,848,910.66 in 2020[19]. - The net profit attributable to shareholders for 2021 was ¥120,201,415.72, a decrease of 14.78% from ¥141,052,780.56 in 2020[19]. - The net profit after deducting non-recurring gains and losses was ¥115,415,204.48, down 14.83% from ¥135,512,748.24 in 2020[19]. - The net cash flow from operating activities increased by 19.71% to ¥199,729,417.14 in 2021, compared to ¥166,849,476.85 in 2020[19]. - The total assets at the end of 2021 were ¥970,306,076.54, a 23.10% increase from ¥788,252,254.49 at the end of 2020[19]. - The net assets attributable to shareholders increased by 19.31% to ¥742,839,394.81 at the end of 2021, compared to ¥622,637,979.09 at the end of 2020[19]. - The basic earnings per share for 2021 was ¥1.75, down 14.63% from ¥2.05 in 2020[19]. - In 2021, the company achieved a revenue of CNY 521.70 million, representing a growth of 9.40% year-over-year, while net profit decreased by 14.78% to CNY 120.20 million[48]. - The average exchange rate of USD to CNY decreased from 6.9346 to 6.4556, resulting in a currency depreciation impact that reduced revenue by CNY 26.40 million[48]. - The cost of goods sold increased by 23.88% year-on-year, primarily due to rising prices of key raw materials, including a 61.22% increase in domestic thionyl chloride and a 51.90% increase in adipic acid[49]. - The gross margin for the pharmaceutical main business decreased to 40.43%, down 6.95% from the previous year, due to increased costs[54]. - Domestic revenue grew significantly by 40.20%, reaching ¥165,980,682.28, while international revenue slightly decreased by 0.77% to ¥355,714,983.67[52]. Research and Development - The company has obtained 31 invention patents and has a complete and professional R&D platform, ensuring continuous optimization of its product pipeline[37]. - The company’s products include three major series: alpha-lipoic acid, phosphatidylcholine, and carnosine, with applications in pharmaceuticals and health products[38]. - The company plans to increase R&D investment in 2022, focusing on the development of key pharmaceutical intermediates and specialty APIs[82]. - The company aims to enhance its R&D team by attracting high-end talent and optimizing the organizational structure to support rapid growth[82]. - The company’s R&D expenses increased by 24.65% year-on-year, reaching ¥28,514,243.16, which represents 5.47% of total revenue[65]. - Research and development expenses rose by 24.65% to ¥28,514,243.16, with a focus on high-end pharmaceutical raw materials and the successful approval of the key project, Arixib, in August 2021[49]. Market and Industry Outlook - The global market for raw materials and intermediates is expected to maintain stable growth, driven by the expiration of patents for original drugs, with an estimated sales value of approximately $198 billion from 2019 to 2024[30]. - The global active pharmaceutical ingredients (API) market was approximately $174.96 billion in 2020 and is projected to reach $245.88 billion by 2026, with a CAGR of 5.84% from 2021 to 2026[31]. - In 2019, China's pharmaceutical raw material manufacturing enterprises achieved main business revenue of 380.37 billion yuan, accounting for 14.6% of the total revenue of large-scale pharmaceutical enterprises in China, with a year-on-year growth of 5.0%[31]. - The Chinese government has issued policies to support the high-quality development of the API industry, emphasizing the development of specialty APIs and innovative APIs[32]. Corporate Governance - The company has a governance structure compliant with laws and regulations, including an independent board of directors and supervisory board[92]. - The company has established independent bank accounts, ensuring no shared accounts with controlling shareholders[92]. - The company has a clear internal management and control system tailored to its operational needs[92]. - The company has appointed independent directors to enhance governance and oversight[94]. - The company held its annual shareholder meeting with 100% investor participation, approving key reports including the 2020 financial report and the 2021 budget[93]. - The company has a total of 5,536,200 shares represented by related shareholders that were excluded from the voting rights during the shareholder meeting[93]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[127]. - The company established a comprehensive environmental protection system combining clean production and end-of-pipe treatment to ensure compliance with pollutant discharge standards[129]. - The company’s wastewater treatment facilities utilize advanced processes such as MVR evaporation and reverse osmosis to meet discharge standards[130]. - The company has received environmental impact assessment approvals for multiple projects, including a 1000 tons/year production of 6,8-dichloro-octanoic acid ethyl ester and related products, approved in November 2010[131]. - The company has maintained compliance with environmental regulations, with no administrative penalties reported during the reporting period[133]. Employee Management - The total number of employees at the end of the reporting period was 466, with 322 in production, 79 in technology, and 6 in sales[113]. - The employee compensation policy combines base salary and performance-based pay, ensuring competitive remuneration[114]. - The company emphasizes talent development through competitive compensation and internal training mechanisms[115]. - The company has established a comprehensive employee social insurance management system, ensuring labor rights and promoting harmonious labor relations[134]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares to all shareholders, based on a total of 91,670,000 shares[4]. - The company distributed a cash dividend of 4.00 RMB per 10 shares, totaling 36,668,000.00 RMB, which represents 100% of the total profit distribution[116][118]. - The company has no plans for stock dividends or capital reserve transfers during the reporting period[118].